Imfinzi (durvalumab) - AstraZeneca
INI-4001 - Inimmune
Tecentriq (atezolizumab) - Roche
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Bavencio (avelumab) - EMD Serono
Keytruda (pembrolizumab) - Merck (MSD)
Libtayo (cemiplimab-rwlc) - Regeneron
Trial of INI-4001 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Oct 17, 2026 - P1 | N=10 | Completed | Sponsor: Inimmune Corporation | Recruiting ➔ Completed | N=50 ➔ 10 | Trial completion date: Mar 2027 ➔ Jun 2026 | Trial primary completion date: Oct 2026 ➔ Jun 2026 
Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
http://clinicaltrials.gov/ct2/show/NCT06302426
 
Oct 17, 2026
 
Prev Next